How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    • Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Belzutifan for treating tumours associated with von Hippel-Lindau disease

Closed for comments This consultation ended on at   Request commenting lead permission

ID3932 Belzutifan for VHL Draft guidance to PM for consultation (no CON).docx

The Department of Health and Social Care has asked the National Institute for Health and Care Excellence (NICE) to produce guidance on using belzutifan in the NHS in England. The evaluation committee has considered the evidence submitted by the company and the views of non-company stakeholders, clinical experts and patient experts.

This document has been prepared for consultation with the stakeholders. It summarises the evidence and views that have been considered, and sets out the recommendations made by the committee. NICE invites comments from the stakeholders for this evaluation and the public. This document should be read along with the evidence (see the committee papers).

The evaluation committee is interested in receiving comments on the following:

  • Has all of the relevant evidence been taken into account?

  • Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?


Note that this document is not NICE's final guidance on this technology. The recommendations in section 1 may change after consultation.

After consultation:

  • The evaluation committee will meet again to consider the evidence, this evaluation consultation document and comments from the stakeholders.

  • At that meeting, the committee will also consider comments made by people who are not stakeholders.

  • After considering these comments, the committee will prepare the final draft guidance.

  • Subject to any appeal by stakeholders, the final draft guidance may be used as the basis for NICE's guidance on using belzutifan in the NHS in England.

For further details, see NICE's manual on health technology evaluation.

The key dates for this evaluation are:

  • Closing date for comments: 03 January 2024

  • Second evaluation committee meeting: 15 February 2023

  • Details of membership of the evaluation committee are given in section 4